UNITED STATES SECURITIES AND EXCHANGE COMMISSION Form 144 Filer Information Washington, D.C. 20549

Form 144

FORM 144

NOTICE OF PROPOSED SALE OF SECURITIES PURSUANT TO RULE 144 UNDER THE SECURITIES ACT OF 1933

144: Filer Information

Filer CIK 0001741533 Filer CCC XXXXXXXX Is this a LIVE or TEST Filing? LIVE TEST Submission Contact Information

Name Phone E-Mail Address

144: Issuer Information

Name of Issuer SEC File Number

Address of Issuer

Phone

Name of Person for Whose Account the Securities are To Be Sold

144: Securities Information

Name and Address of

the Broker

See the definition of "person" in paragraph (a) of Rule 144. Information is to be given not only as to the person for whose account the securities are to be sold but also as to all other persons included in that definition. In addition, information shall be given as to sales by all persons whose sales are required by paragraph (e) of Rule 144 to be aggregated with sales for the account of the person filing this notice.

Relationship to Issuer

Title of the Class of

Securities To Be Sold

Shares or Approximate

Other Units Date of Sale

Name the **Securities** -1 íe

		To Be Sold	Value	Outstandin	g	Exchange
Common	Charles Schwab & Co., Inc. 3000 Schwab Way Westlake TX 76262	29000	508370.00	35238254	09/05/2023	NASDAQ

Number of

Shares or

Other Units

Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold

Title of the Name of Person Is Amount of Date of Date you Nature of Date Nature of Class Acquired Acquisition from Whom this Donor **Securities** Payment Payment *

Kiniksa Pharmaceuticals, Ltd. 001-38492 CLARENDON HOUSE 2 CHURCH STREET HAMILTON **BERMUDA** HM11 7814399100 Paolini John F.

Officer

Number of

Aggregate

Market

	Transaction	Acquired	a Gift?	1	Acquired	
Common	Employee Stock 09/05/2023 Option Exercise - see Remarks				29000	Broker Payment 09/05/2023 for Cashless Exercise

* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.

Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

Name and Address of Seller	Title of Securities Sold	Date of Sale	Amount of Securities Sold	Gross Proceeds
John F. Paolini CLARENDON HOUSE 2 CHURCH STREET HAMILTON D0 HM11	Kiniksa Pharmaceuticals, Ltd.	07/25/2023	29000	555201.00

144: Remarks and Signature

Remarks	The options covered by this filing may be sold over various dates.
Date of Notice	09/05/2023
Date of Plan Adoption or Giving of Instruction, If Relying on Rule 10b5-1	05/05/2023
ATTENTION:	

The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date. Signature John F. Paolini

ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)